Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Commentary|Articles|June 12, 2026
Targeted Therapies, Frontline Combos Headline Key Lung Cancer Data to Emerge From ASCO 2026
Author(s)Caroline Seymour
Fact checked by: Tracy Ann Politowicz, Chris Ryan
Experts recap of the most pivotal lung cancer data to surface at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
As data emerged across the non–small cell lung cancer (NSCLC) space at the 2026 ASCO Annual Meeting, experts from the field outlined some of the most crucial findings that could impact future clinical approaches.
Related to this article
TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
Faculty at an OncLive Scientific Interchange and Workshop discussed factors that help inform treatment selection in advanced EGFR-mutated NSCLC.
IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
IBI363 plus bevacizumab extended progression-free survival vs docetaxel in patients with immunotherapy-resistant lung adenocarcinoma in a randomized phase 1b study.
Advertisement
Advertisement